Simcere Pharma nets $461m from top-end pricing

biopharma_stocks_adobe_575x375.jpg
By Jonathan Breen
20 Oct 2020

Simcere Pharmaceutical Group has bagged HK$3.57bn ($460.6m) from its IPO, after sealing the offer at the top end of the price guidance, according to a source familiar with the deal.

Simcere is a Chinese firm that focuses on the research and development, manufacture and sale of generic pharmaceuticals covering oncology, the central nervous system and autoimmune diseases.

The issuer hit the Hong Kong market at the start of last week offering 260.6m shares at HK$12.10 and HK$13.70. It ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial